Abstract:7097 Background: Recently, two studies by Paez and Lynch show that somatic mutations in EGFR tyrosine kinase(TK) domain are associated with sensitivity of NSCLC to gefitinib. The mutations were clustered around ATP-biding pocket of the TK domain. Mutations were more frequent in women, adenocacinomas or bronchoalveolar carcinoma (BAC) and non-smoker patients. Interestingly, these studies showed the frequency of mutations is 2%–8% in Caucasian patient population compared to 26% in Japanese patients. Pao also report that 88% of these mutations are located at two “hotspots”(exon 19 and 21). This result also prompted us to perform analysis of EGFR mutations particularly on exon 19 and 21 in Chinese patients. Methods: All patients were pathologically confirmed NSCLC who had not been exposed to gefitinib. Fresh frozen tumor specimens and matched normal tissue were obtained from 56 consecutive patients during surgical operation. DNA was isolated by Proteinase K digestion, followed by traditional Phenol-chloroform extraction procedures. PCR was performed using the Takara Taq™ system (Takara Bio, Otsu, Japan). PCR amplification fragments were then sequenced and analyzed in both sense and antisense directions, using Beckman Coulter CEQ8000 Genetic analysis system and the CEQ™ DTCS Quick Start Kit (Beckman Coulter). Results: Somatic mutations in the TK domain of EGFR were identified from 9 of 56 (16.1%) patients. Among the 9 mutants, 6 showed in-frame deletions in exon 19 (delE746-A750 and delL747-S752). Another 3 showed substitutions leucine to arginine at position 858 (L858R) in exon 21. Mutations were more frequent in BAC (40%) and adenocarcinoma (28%) than in squamous carcinoma (0%), more frequent in women (21.4%) than in men (14.3%), and more frequent in non smokers (23.8%) than in smokers (11.4%). The highest fraction of mutations was detected in women with adenocarcinoma (42.9%). Conclusions: The status of EGFR mutations on exon 19 and exon 21 in Chinese patients with NSCLC are similar to Japanese patients, and the frequency of EGFR mutations in Chinese patients is higher than that in Caucasian patients (16.1% vs 2–8%). No significant financial relationships to disclose.

Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.

[Mutations in Exon 19 of EGFR Gene in Non-Small Cell Lung Cancer from Chinese Patients].

EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.

Cmar_a_200126 6139..6150

HER-2 Mutations in Chinese Lung Adenocarcinoma Patients with Negative EGFR Mutations.

P1.01-85 the Prevalence of Different EGFR Exon20 Mutations in 12,833 Chinese Lung Cancer Patients

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations

Prognostic Analysis of Patients with Mutant and Wild-Type EGFR Gene Lung Adenocarcinoma

Epidermal growth factor receptor mutations in Chinese patients with adenocarcinoma of the lung

Prognostic Outcomes and Recurrence Patterns in Resected Stage I Lung Adenocarcinoma Harbouring Atypical Epidermal Growth Factor Receptor Mutations.

Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma.

P1.25-18 Prognostic Impact of Exon20 Insertion in Surgically Resected Lung Adenocarcinoma Harboring Atypical EGFR Single Mutation

Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

Egfr Exon 19 Insertions: A New Family of Sensitizing Egfr Mutations in Lung Adenocarcinoma

[Epidermal Growth Factor Receptor Gene Mutations and Clinicopathologic Correlation in 309 Patients with Non-Small Cell Lung Cancer].

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Detection of EGFR Gene Mutation in Lung Adenocarcinoma and its Clinical Analysis

Mutational analysis of exons 19 and 21 of the EGFR gene in lung adenocarcinoma

The Mutation Profile of EGFR in Resectable Chinese Lung Cancer Patients.

The Status of Epidermal Growth Factor Receptor (EGFR) Mutations at Exon 19 and 21 in Chinese Patients with NSCLC